

Management:

Prof. Aaron Palmon, PhD DMD
Founder & President

Hebrew University, Faculty of
Dental Medicine, Dean.

Omer Deutsch, PhD DMD
Founder & CEO

Guy Krief, PhD
Founder & Deputy CEO, CBDO

Yoav Neumann, PhD
Founder & CFO

Raluca Stiubea-Cohen, PhD
Founder & CSO

Advisory Board:

Prof. Max Herzberg, PhD
Chairman

Seth Salpeter, PhD

Moshe Deutsch, CPA

Industry:

OTC diagnostics & Public Health

Key Innovation:

Saliva based diagnostics

Current Investors:

Hebrew University
Private investors

Launch date:

January 2015

Contact:

Telefax: +972 2 672-7827


info@salignostics.com

JBP, Hadassah Ein Kerem
Jerusalem
ISRAEL

**Approved and supported by
the Israel Innovation
Authority** (Office of the Chief
Scientist)

The Rapid Diagnostic Tests (RDT) Market

- 2023 Expected revenue is **US\$38.1 Billion**
- 5 years **CAGR** of **10%**.
- **~80%** of the market are **Home-use oriented**.
- *Currently* most of commercialized products are based on *Blood, Urine* and *Feces*.
- These products are *sub-optimal* for actual *home-use*.



Who are we...?

Salignostics Ltd is an R&D company, focuses in **Saliva Based Diagnostics** solutions.

Our assets:

- **Novel Intellectual property**
- **Innovative technologies and products**
- **Expert and trained team**

Our Vision:

To shape the next generation of OTC diagnostics utilizing saliva based diagnostic solutions, with a user friendly, cleaner, safer, cheaper, rapid and accessible tests.

Salignostics considers its group of founders as the source of growth and potential development in terms of future intellectual property and technological innovations.

Products

PregKit®

Saliva Based Pregnancy Test.

- Estimated market size: ~\$US2 Billion
- November 2014 – Seed fundraise.
- Clinical trials (Among ~100 women): Pregnancy is detected in saliva 1-2 days after missed period.

MalKit®

Saliva based RDT for Malaria diagnosis.


- Estimated market size: ~\$US1.1 Billion
- Worldwide efforts- [WHO](#), Governments, NGOs as [Bill & Melinda Gates Foundation's](#).
- **Uganda Africa, May 2018**-Successful second preliminary clinical trial was conducted, showing a positive clinical correlation between blood and saliva samples.

PyloriKit®

Saliva based RDT for Helicobacter Pylori infection

- One of the most common bacterial infection in human: ~50% of world population
- Major factor of upper gastrointestinal (GI) complications
- Estimated market size: ~\$US2.5 Billion
- Initial pre-clinical trials: successful diagnosis of H.Pylori infection by RDT with saliva samples.

Clinical Trials: Early Pregnancy*



Saliva + Salignostics' Technologies
POSITIVE DETECTION


Saliva Only
NO DETECTION

* Performed with Salignostics' own saliva tests



Malaria Clinical Trial (May 2018, Uganda)

Clinical Trials: Helicobacter Pylori**



Saliva + Salignostics' Technologies
POSITIVE DETECTION

Saliva Only
NO DETECTION

** Performed with commercial feces tests